Four different vaccines against the coronavirus are now authorized in France.

While the use of the AstraZeneca product is suspended in some European countries, some French people are worried about the multiplicity of vaccines on the market.

Dominique Le Guludec, president of the High Authority for Health, wanted to be reassuring, Saturday on Europe 1.

INTERVIEW

With the green light granted to the Janssen product from the Johnson & Johnson laboratory, four vaccines against Covid-19 are now authorized in France.

Faced with the profusion of vaccines, launched with great fanfare, and the controversy around possible serious side effects, some French people are worried.

"We should not wonder but rejoice," said the president of the High Authority for Health, Dominique Le Guludec, at the microphone of Europe 1. According to her, the diversity of products available is a major asset to come at the end of the pandemic.

"Each vaccine has its own unique properties. The whole world needs it, I take it as an opportunity."

>> LIVE

- Coronavirus: follow the evolution of the situation on Saturday March 13

"Obviously a number of laboratories have tried, all have not succeeded ... or not immediately succeeded", continues the president of the HAS who expects the arrival of new vaccines, candidates for marketing. .

The case of the French laboratory Sanofi seems scrutinized with attention, when the latter launches the trials of a second formula after a dismal failure: "We will need all the vaccines. We will examine the Sanofi file as soon as it arrives to determine its place in the vaccine strategy. "

>> More info to follow